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In 1992, the American Cancer Society (ACS) recommended annual screening for prostate cancer for men
50 and older using PSA. In this article, I introduce a method to use race and age-specific PSA accuracy
data to evaluate differences in the valuation of outcomes by race and age that were expressed by the ACS
guidelines. Using this new method, it can be concluded that the guidelines implied a 4-fold greater
valuation was assigned to screening young white males with prostate cancer than the value that was
assigned to young black males with cancer. Future implementation of guidelines for screening and
testing should recognize and rectify any social inequities that are expressed via their implementation.
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Abstract
In 1992, the American Cancer Society (ACS) recommended annual
screening for prostate cancer for men 50 and older using PSA. In this
article, I introduce a method to use race and age-specific PSA accuracy
data to evaluate differences in the valuation of outcomes by race and
age that were expressed by the ACS guidelines. Using this new method,
it can be concluded that the guidelines implied a 4-fold greater valuation was assigned to screening young white males with prostate cancer
than the value that was assigned to young black males with cancer.
Future implementation of guidelines for screening and testing should
recognize and rectify any social inequities that are expressed via their
implementation.
Key Words: diagnostic technology, health policy, ROC Curve, PSA,
prostate cancer

Introduction
The aphorism ‘actions speak louder than words’ is no less true in
Medicine than it is elsewhere. When actions are the result of decisionmaking, they then express something about the decision-maker. The
action of a 17-year-old driver careening 100 mph on a highway expresses
a relative valuation on life versus death and of the relative likelihood of
these two outcomes in the mind of the decision-maker. In equal parts,
the 1992 recommendations of the American Cancer Society1 for prostate
cancer screening beginning at age 50 using Digital Rectal Examination
(DRE) and PSA with threshold 4.0 ng/ml expresses something about the
relative valuation and likelihood of the outcomes of screening diseased
and non-diseased individuals held by implementers of those guidelines.
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A rational decision maker uses diagnostic technology in such a way
so as to maximize the benefit from the technology while minimizing the
cost. Whether or not the ways diagnostic technologies are actually used
in medicine comes about from rational decision processes, the perspective of the rational decision-maker can always be relied upon to provide
a universally acceptable referent, much as is done in Economics. This
reference perspective can, among other things, provide a consistent
framework for interpreting observed behavior.
In this paper, I adopt the perspective of the rational decision-maker
to derive a measure of the relative valuation of health outcomes that is
expressed by the observed use of a diagnostic technology in a clinical
population. The method inverts a fundamental result from Clinical Decision Analysis that is used to optimize the use of a diagnostic technology.
As an example, I apply this method to then use race and age specific data
published about the accuracy of PSA testing to determine the relative
valuations that were expressed by 1992 ACS guidelines for the screening
of prostate cancer using PSA.1 The 1992 guidelines were selected solely
to provide an example of the method and the insights the method can
provide. My paper does not attempt to evaluate guidelines currently
used in practice.

Methods
The choices involved in the application of a diagnostic technology
in a defined clinical population are expressed in something called the
“Receiver Operating Characteristic (ROC) Curve.”2 The ROC Curve
is a graphical display of all of the Sensitivity-False Positive Probability
combinations that are possible by the selection of various thresholds.
For example, application of the PSA test requires selection of a threshold
value to define a positive test result. Recommendations made by the ACS
in 1992 were for 4.0 ng/ml1 and this cutoff provides an estimated Sensitivity and False Positive Probability for white males 70-79 years old of
98.6% and 26.9%, respectively3. Each such threshold selection provides a
different True Positive-False Positive probability combination. Selection
of other thresholds yields other combinations and the entire set of such
combinations can be graphically displayed in the ROC Curve. Figure 1,
for example, plots the ROC curve for PSA when applied to white males
70-79 years old. The curve is estimated from data published by Morgan.3
To implement a diagnostic technology, a rational decision-maker determines the threshold value that maximizes benefit and minimizes cost.
Fortunately, the solution, well known in the Clinical Decision Analysis
literature, is straightforward.4 The rational decision maker selects the
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FIGURE 1. ROC Curve of PSA for white men 70-79. Each point on the curve represents the
sensitivity-false positive probability arising from the selection of a threshold for PSA
testing.

threshold at which the slope of the ROC Curve equals the product of the
relative probability of non-disease times the relative value of applying
the test in the non-diseased versus the diseased populations.4,5 In shorthand, this can be expressed as:
Choose the threshold at which,
ROC Slope = (Relative probability of Non-disease)(Relative Value of Non-disease)

To anchor these terms, it helps to note that the “Relative Probability of
Non-disease” is the odds of not having disease. That is, if “p” is the prevalence
of disease in the population, then (Relative Probability of Non-disease) = (1p)/p. Although it is not necessary to restrict the measurement of outcomes to
monetary units, it is helpful to think about the term “Relative Value of Nondisease” in terms of costs. Let “cTP”, “cFN”, “cFP” and “cTN” represent the “costs”
related to True Positives, False Negatives, False Positive and True Negatives
(negative cost implies benefit). Then, Relative Value of Non-disease = (cTNcFP)/(cTP-cFN)4.
The previous relationship can be inverted. If we observe the use of a
diagnostic technology, and if we have knowledge of the odds of non-dis-
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ease and of the ROC Curve of the technology, we can then infer the relative valuation of outcomes by the rational decision-maker: The Relative
Value (non-diseased to diseased) that is expressed by the rational use of a
diagnostic technology equals the “Relative Probability of Disease” times
the slope of the ROC Curve at the point observed to be used in practice.
Symbolically,
Expressed Relative Value of Non-diseased =
(Relative probability of Disease)(ROC Slope)
where “Relative Probability of Disease” is the odds of disease= p/(1-p).

It is important to point out that computation of this measure requires
the computation of the slope of the ROC Curve at the operating point
used in practice. Hence, the analyst must have first the ROC Curve of
the technology. This can be accomplished by appropriately designed and
conducted technology assessment studies. Hopefully, such studies can be
sourced from the literature.

Results
Table 1 presents the results of the application of this new method. In
1992, the American Cancer Society1 recommended annual screening for
prostate cancer for men 50 and older using both DRE and PSA. Here, I
consider only the implications of the ACS recommendation of PSA-based
screening for prostate cancer using the threshold of 4.0 ng/ml. Morgan3
estimated ROC Curves for PSA testing in the detection of prostate cancer
for various age groups of white and black men. I then used this data to
estimate the slope of each ROC Curve at the ACS-recommended threshold for each age-race specific ROC Curve after assuming that PSA levels
are normally distributed. Estimates of age and race specific prevalence
were obtained from SEER tables6 and were then used to estimate the
odds of disease. The relative value of outcomes (no prostate cancer vs.
prostate cancer) expressed by the ACS guidelines was then computed using the previous formula. This number is reported as “Relative Value of
Non-diseased” in the table. To facilitate interpretation, the reciprocal also
appears in the table and is denoted by “Relative Value of Diseased.” This
value can be interpreted as the value of outcomes in applying the screening test to the population with prostate cancer relative to the value when
screening the population without prostate cancer.
Focusing on “Relative Value of Diseased,” we can observe that
screening young men (40-49) for prostate cancer had greater expressed
relative value than screening older men in both racial groups. However,
some racial disparities in this pattern do occur. For example, the relative
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TABLE 1. Relative values in prostate cancer screening expressed by 1992 ACS guidelines.
Whites

Relative Value

Age

Slope

Prevalence

Non-Diseasedc

Diseasedd

40-49

4.341

9.1

0.000395

2531.645570

50-59

5.453

146.75

0.008016

124.750499

60-69

3.211

713.8

0.023084

43.320049

70-79

1.833

1353.45

0.025149

39.763012

a

b

Blacks

Relative Value

Age

Slope

Prevalence

Non-Diseasedc

Diseasedd

40-49

7.654

15.7

0.001202

831.946755

50-59

0.898

273.45

0.002462

406.173842

60-69

0.431

1086.5

0.004734

211.237854

70-79

0.108

1868.1

0.002056

486.381323

a

b

Based on cutoff of 4.0 ng/ml
b
Per 100,000/year
c
Value of outcomes from screening men without cancer relative to the value from screening men with cancer
d
Value of outcomes from screening men with cancer relative to the value from screening men without cancer
a

value of screening steadily declines with increasing age for white males.
This is consistent with the opinion that the effectiveness of screening for
and treatment of prostate cancer declines with advancing age. However,
this pattern is not strictly followed for black males. The 1992 ACS guidelines suggested that the relative value of screening is less for black males
in the age groups 50-59 and 60-69 than it is for males from the oldest age
group (70-79).
Another salient observation from the table is that the relative value
of screening young white men is at least 20 times larger than the expressed value of screening white men from any other white age group.
On the other hand, the relative values for black males are much more
homogeneous. The relative value of screening a young black male is at
most 4 times that of screening black males from another age group.
Finally, we can observe that if the value of health outcomes in screening young healthy men were the same for both racial groups, then the
guidelines express a four-fold greater valuation for screening young
white males (40-49) with prostate cancer than the value assigned to
young black males.

Discussion
The value of health outcomes that is expressed by the use of a diagnostic technology is the relative value implied had a rational decision
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maker aware of the disease prevalence and operating characteristics of
the technology in the clinical population of interest implemented the
technology. What better perspective is there to understand the implications of the observed use of diagnostic technology than from the universally-accepted perspective of rationality? Is there a decision-maker not
willing to affirm that it is best, when possible, to maximize benefit and
minimize cost?
Had the 1992 ACS recommendations been made from a rational
perspective, we would conclude that the maker of these recommendations valued outcomes quite differently for white and black men. The
monotonicity of declining values for white men seems to be logical since
one might anticipate the benefits from screening to decline with age. This
coherent pattern does not hold for black males. Is this anomaly acceptable to modern thought in Medicine?
The ACS recommendations also express an astronomically high
value for screening young white men compared to young black men.
This discrepancy, although probably unintended, nonetheless expresses
a substantial inequity. Is this desirable?
The utility of the measure introduced in this paper is that it provides
a universally acceptable metric with which individuals having widely
varying perspectives can commonly view the implications of the use of
diagnostic technology. It is not important whether rational decision making processes were actually followed when the diagnostic technology
was implemented. The goal is simply to provide a universal frame-of-reference for measurement, communication and discovery.
Limitations
A limitation of this paper is that it provides only the essential background required to understand and apply this new measure. The reader
considering use of this measure should consult the burgeoning literature
that has arisen over the past twenty years around ROC Curves in particular and the evaluation of diagnostic technologies in general. Recently,
two comprehensive overviews have appeared in book form.7,8
I have focused this analysis on the 1992 ACS guidelines simply in
the hope that distance in time will promote objective discussion of this
new methodology. Another limitation of the current paper is the focus
on PSA screening and not PSA combined with DRE as was considered by
the guidelines. However, this limitation points out the need for data to be
collected that provides the ROC curve of PSA combined with DRE stratified by race and age. Analysis with contemporary data and contemporary guidelines should of course be conducted. If such findings replicate
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the findings made in this paper, then we might seek to fashion health
policy for the use of PSA in screening that is specifically directed at lessening expressed racial inequities. How would this be accomplished? The
rationalist approach tells us to first establish the value of health outcomes
for each age group and consider these as equal for both racial groups.
Then, using updated ROC Curves, select PSA testing thresholds that are
optimal for each age-race group.
In general, the methodology introduced in this paper introduces
a vantage point with which the implications of the use of diagnostic
technology can be quantitatively assessed. Hopefully, awareness of the
implications of our actions in screening and diagnosis gained through
the use of similar analyses will point the direction to improved health
care by lessening unintended, yet nonetheless expressed, inequalities.
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